A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Cohen
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 23363
Ponce, Puerto Rico
- Site Reference Id/investigator# 23392
Phoenix, Arizona, United States
- Site Reference Id/investigator# 23370
Anaheim, California, United States
- Site Reference Id/investigator# 23387
La Jolla, California, United States
- Site Reference Id/investigator# 23388
Los Angeles, California, United States
- Site Reference Id/investigator# 23371
Aurora, Colorado, United States
- Site Reference Id/investigator# 23369
Orlando, Florida, United States
- Site Reference Id/investigator# 26362
Orlando, Florida, United States
- Site Reference Id/investigator# 23373
Chicago, Illinois, United States
- Site Reference Id/investigator# 24908
Chicago, Illinois, United States
- Site Reference Id/investigator# 23381
Indianapolis, Indiana, United States
- Site Reference Id/investigator# 23372
Baton Rouge, Louisiana, United States
- Site Reference Id/investigator# 24710
New Orleans, Louisiana, United States
- Site Reference Id/investigator# 23391
Baltimore, Maryland, United States
- Site Reference Id/investigator# 23377
Detroit, Michigan, United States
- Site Reference Id/investigator# 24909
Saint Paul, Minnesota, United States
- Site Reference Id/investigator# 23379
New York, New York, United States
- Site Reference Id/investigator# 35842
New York, New York, United States
- Site Reference Id/investigator# 23375
Chapel Hill, North Carolina, United States
- Site Reference Id/investigator# 23385
Durham, North Carolina, United States
- Site Reference Id/investigator# 23376
Dallas, Texas, United States
- Site Reference Id/investigator# 24891
Houston, Texas, United States
- Site Reference Id/investigator# 23382
San Antonio, Texas, United States
- Site Reference Id/investigator# 24715
Salt Lake City, Utah, United States
- Site Reference Id/investigator# 25463
Seattle, Washington, United States
- Site Reference Id/investigator# 23383
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2010
- Primary completion
- 30 Jun 2011
- Completion
- 31 Jan 2012
- Last update posted
- 8 Jan 2015
- Registered enrollment
- 74
- Registry id
- NCT01074008
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.